Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 305-701, Republic of Korea.
Department of Chemical and Biological Engineering, Korea National University of Transportation, Chungju, Chung-Buk 27469, Republic of Korea.
ACS Appl Bio Mater. 2024 Sep 16;7(9):6025-6033. doi: 10.1021/acsabm.4c00658. Epub 2024 Sep 4.
Liposomes are applied to various anticancer treatments as representative drug delivery carriers. However, liposomes do not have their own targeting properties; therefore, there are limitations in drug delivery to specific tissues or cells. High targetability in drug delivery is an important factor in improving bioavailability and drug efficacy and reducing side effects; recent research has been actively investigated to modify the surface of liposomes to give them specific functions. In this study, we studied a drug delivery system for anticancer treatment that enhances targeting ability through fusion with exosomes on the surface of liposomes. We designed exosome-liposome hybrid nanoparticles loaded with a gemcitabine prodrug as a treatment for pancreatic ductal adenocarcinoma (PDAC). Membrane fusion with exosomes shows excellent targeting ability to pancreatic cancer cells due to intrinsic targeting ability and expansion of the macropinocytosis pathway.
脂质体作为代表性的药物递送载体，被应用于各种抗癌治疗中。然而，脂质体本身没有靶向特性；因此，在将药物递送到特定组织或细胞方面存在局限性。在提高生物利用度和药物疗效、降低副作用方面，药物递送的高靶向性是一个重要因素；最近的研究积极探索了对脂质体表面进行修饰，赋予其特定功能。在这项研究中，我们研究了一种通过与脂质体表面的外泌体融合来增强靶向能力的抗癌治疗药物递送系统。我们设计了负载吉西他滨前药的外泌体-脂质体杂合纳米颗粒作为治疗胰腺导管腺癌 (PDAC) 的药物。由于内在的靶向能力和巨胞饮途径的扩展，与外泌体的膜融合显示出对胰腺癌细胞的优异靶向能力。
